252 related articles for article (PubMed ID: 22495819)
21. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.
Ferreira LB; Eloy C; Pestana A; Lyra J; Moura M; Prazeres H; Tavares C; Sobrinho-Simões M; Gimba E; Soares P
Eur J Endocrinol; 2016 Apr; 174(4):551-61. PubMed ID: 26811408
[TBL] [Abstract][Full Text] [Related]
23. Suppressing tumourigenicity of prostate cancer cells by inhibiting osteopontin expression.
Zhang Y; Forootan SS; Kamalian L; Bao ZZ; Malki MI; Foster CS; Ke Y
Int J Oncol; 2011 Apr; 38(4):1083-91. PubMed ID: 21290088
[TBL] [Abstract][Full Text] [Related]
24. [P2Y purinergic receptor activated PI-3K/Akt signaling pathway in regulation of growth and invasion of prostatic cancer].
Wang YX; Shi YH; Gong LH; Li Y; Heng WJ; You JF; Zhong HH; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2007 Oct; 36(10):681-6. PubMed ID: 18194602
[TBL] [Abstract][Full Text] [Related]
25. Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma.
Jámbor K; Koroknai V; Kiss T; Szász I; Pikó P; Balázs M
Pathol Oncol Res; 2022; 28():1610608. PubMed ID: 36091936
[TBL] [Abstract][Full Text] [Related]
26. Lung cancer osteopontin isoforms exhibit angiogenic functional heterogeneity.
Blasberg JD; Goparaju CM; Pass HI; Donington JS
J Thorac Cardiovasc Surg; 2010 Jun; 139(6):1587-93. PubMed ID: 19818970
[TBL] [Abstract][Full Text] [Related]
27. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
[TBL] [Abstract][Full Text] [Related]
28. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
Desai B; Rogers MJ; Chellaiah MA
Mol Cancer; 2007 Mar; 6():18. PubMed ID: 17343740
[TBL] [Abstract][Full Text] [Related]
29. Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
Dizeyi N; Hedlund P; Bjartell A; Tinzl M; Austild-Taskén K; Abrahamsson PA
Urol Oncol; 2011; 29(4):436-45. PubMed ID: 19926313
[TBL] [Abstract][Full Text] [Related]
30. OPNa Overexpression Is Associated with Matrix Calcification in Thyroid Cancer Cell Lines.
Ferreira LB; Lima RT; Bastos ACSDF; Silva AM; Tavares C; Pestana A; Rios E; Eloy C; Sobrinho-Simões M; Gimba ERP; Soares P
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274371
[TBL] [Abstract][Full Text] [Related]
31. SB225002 inhibits prostate cancer invasion and attenuates the expression of BSP, OPN and MMP‑2.
Xu M; Jiang H; Wang H; Liu J; Liu B; Guo Z
Oncol Rep; 2018 Aug; 40(2):726-736. PubMed ID: 29917166
[TBL] [Abstract][Full Text] [Related]
32. Identification and quantification of osteopontin splice variants in the plasma of lung cancer patients using immunoaffinity capture and targeted mass spectrometry.
Wu J; Pungaliya P; Kraynov E; Bates B
Biomarkers; 2012 Mar; 17(2):125-33. PubMed ID: 22188260
[TBL] [Abstract][Full Text] [Related]
33. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
34. Expression of a prometastatic splice variant of osteopontin, OPNC, in human pancreatic ductal adenocarcinoma.
Sullivan J; Blair L; Alnajar A; Aziz T; Ng CY; Chipitsyna G; Gong Q; Witkiewicz A; Weber GF; Denhardt DT; Yeo CJ; Arafat HA
Surgery; 2009 Aug; 146(2):232-40. PubMed ID: 19628079
[TBL] [Abstract][Full Text] [Related]
35. Osteopontin and splice variant expression level in human malignant glioma: radiobiologic effects and prognosis after radiotherapy.
Güttler A; Giebler M; Cuno P; Wichmann H; Keßler J; Ostheimer C; Söling A; Strauss C; Illert J; Kappler M; Vordermark D; Bache M
Radiother Oncol; 2013 Sep; 108(3):535-40. PubMed ID: 23891093
[TBL] [Abstract][Full Text] [Related]
36. Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.
Castellano G; Malaponte G; Mazzarino MC; Figini M; Marchese F; Gangemi P; Travali S; Stivala F; Canevari S; Libra M
Clin Cancer Res; 2008 Nov; 14(22):7470-80. PubMed ID: 19010864
[TBL] [Abstract][Full Text] [Related]
37. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
38. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis.
Fang J; Ding M; Yang L; Liu LZ; Jiang BH
Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033
[TBL] [Abstract][Full Text] [Related]
39. Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance.
Mirzaei A; Mohammadi S; Ghaffari SH; Yaghmaie M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
Asian Pac J Cancer Prev; 2018 Mar; 19(3):615-623. PubMed ID: 29580029
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin has a protective role in prostate tumor development in mice.
Danzaki K; Kanayama M; Alcazar O; Shinohara ML
Eur J Immunol; 2016 Nov; 46(11):2669-2678. PubMed ID: 27601131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
